The Immuno-Oncology Portal was funded by an unrestricted grant from :

    • 6 pharmaceutical companies, each of which contributed the same amount of funding:
  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck Sharp & Dohme
  • Merck KGaA
  • Pfizer
  • Roche
  • The Cancer Drug Development Forum – CDDF, a not-for-profit organization aiming to provide a unique platform to facilitate interactions between academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessment agencies to improve the efficiency of cancer drug development.

 

ECPC shared advanced drafts of the content of the IOP with its funders to obtain their insights and benefit from their knowledge and their experience. 

 

However, the content of the IOP was not influenced by its funders, with ECPC maintaining full editorial control over its contents.

 

 

To find out more about the ECPC Statute and its funding policies, click here.